1. Home
  2. CGEN vs TAYD Comparison

CGEN vs TAYD Comparison

Compare CGEN & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEN
  • TAYD
  • Stock Information
  • Founded
  • CGEN 1993
  • TAYD 1955
  • Country
  • CGEN Israel
  • TAYD United States
  • Employees
  • CGEN N/A
  • TAYD N/A
  • Industry
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • TAYD Industrial Machinery/Components
  • Sector
  • CGEN Health Care
  • TAYD Industrials
  • Exchange
  • CGEN Nasdaq
  • TAYD Nasdaq
  • Market Cap
  • CGEN 167.4M
  • TAYD 138.3M
  • IPO Year
  • CGEN 2000
  • TAYD N/A
  • Fundamental
  • Price
  • CGEN $1.53
  • TAYD $46.53
  • Analyst Decision
  • CGEN
  • TAYD
  • Analyst Count
  • CGEN 0
  • TAYD 0
  • Target Price
  • CGEN N/A
  • TAYD N/A
  • AVG Volume (30 Days)
  • CGEN 236.0K
  • TAYD 31.1K
  • Earning Date
  • CGEN 08-06-2025
  • TAYD 08-14-2025
  • Dividend Yield
  • CGEN N/A
  • TAYD N/A
  • EPS Growth
  • CGEN N/A
  • TAYD 1.48
  • EPS
  • CGEN N/A
  • TAYD 2.50
  • Revenue
  • CGEN $27,589,000.00
  • TAYD $42,796,782.00
  • Revenue This Year
  • CGEN N/A
  • TAYD $15.06
  • Revenue Next Year
  • CGEN $105.77
  • TAYD $8.37
  • P/E Ratio
  • CGEN N/A
  • TAYD $18.25
  • Revenue Growth
  • CGEN N/A
  • TAYD N/A
  • 52 Week Low
  • CGEN $1.13
  • TAYD $29.50
  • 52 Week High
  • CGEN $2.66
  • TAYD $64.50
  • Technical
  • Relative Strength Index (RSI)
  • CGEN 41.35
  • TAYD 59.10
  • Support Level
  • CGEN $1.49
  • TAYD $43.96
  • Resistance Level
  • CGEN $1.64
  • TAYD $47.70
  • Average True Range (ATR)
  • CGEN 0.08
  • TAYD 1.72
  • MACD
  • CGEN -0.02
  • TAYD -0.19
  • Stochastic Oscillator
  • CGEN 25.00
  • TAYD 64.76

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

Share on Social Networks: